First Genetically Edited Cows Arrive at UC Davis
By Edward Ortiz,
Sacramento Bee
| 12. 20. 2015
Untitled Document
The two calves that grace a muddy pen on the UC Davis campus will never grow horns typical of their breed. Instead, they’ll always sport soft hair on the parts of their heads where hard mounds normally emerge.
Named Spotigy and Buri, the calves were designed in a petri dish at a Minnesota-based genetics lab, with the goal of making them easier to pack into pens and trucks without the nuisance of their horns taking up valuable space. Their offspring may also lack horns, and generations of hornless cows could follow, potentially saving the dairy and cattle industry millions of dollars, said Alison Van Eenennaam, a geneticist at UC Davis’ College of Agriculture and Environmental Sciences who worked with the Minnesota lab Recombinetics.
This first-of-a-kind result of a process called genetic editing is a test run that’s expected to deeply impact the cattle and dairy industry and the entire food supply, Van Eenennaam said. It’s also part of a flurry of research looking at how to make cattle easier to maintain, transport and turned into food. The research...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...